Aura 2016 Supplementary data

AURA 2016

Supplementary data

© Commonwealth of Australia 2016

This work is copyright. It may be reproduced in whole or in part for study or training purposes, subject to the inclusion of an acknowledgement of the source.

Address requests and inquiries concerning reproduction and rights for purposes other than those indicated above in writing to:

AURA – Commonwealth Programs, Australian Commission on Safety and Quality in Health Care, GPO Box 5480, Sydney NSW 2001

or email [e-mail]

Suggested citation: Australian Commission on Safety and Quality in Health Care (ACSQHC). AURA 2016: supplementary data. Sydney: ACSQHC, 2016.

An online version of this report can be accessed at www.safetyandquality.gov.au.

ISBN: 978-1-925224-43-6 (print) 978-1-925224-44-3 (online)

Acknowledgements

Many individuals and organisations gave their time and expertise over an extended period to this report, and the Antimicrobial Use and Resistance in Australia (AURA) project, which were undertaken by the Commission. In particular, the Commission wishes to thank the Australian Government Department of Health, the Australian Group on Antimicrobial Resistance, the National Centre for Antimicrobial Stewardship, SA Health, Queensland Health, Pathology Queensland, Sullivan Nicolaides Pathology, NPS MedicineWise, the National Neisseria Network, the Australian Mycobacterium Reference Laboratory Network, and other key experts who have provided their time and considered advice. The involvement and willingness of all concerned to share their experience and expertise are greatly appreciated.

Members of the AURA Project Reference Group are Professor John Turnidge, Dr Phillipa Binns, Professor Marilyn Cruickshank, Dr Jenny Firman, Ms Aine Heaney, Mr Duncan McKenzie, Adjunct Professor Kathy Meleady, Dr Brett Mitchell, Professor Graeme Nimmo, Dr Alicia Segrave, Professor Karin Thursky, Dr Morgyn Warner, Professor Roger Wilson and Associate Professor Leon Worth.

The members of the Commission’s AURA team are also acknowledged for their significant contribution to the development of the AURA Surveillance System and this report.

Disclaimer

This report is based on the best data and evidence available at the time of development.

Edited and designed by Biotext Pty Ltd

Contents

Contents 3

Introduction 4

Sources of data for antimicrobial use and appropriateness 4

Sources of data for antimicrobial resistance 4

AURA 2016 Chapter 3: antimicrobial use and appropriateness tables 6

Table S3.1 Number of hospitals contributing to the National Antimicrobial Utilisation Surveillance Program, by peer group, 2005–14 6

Table S3.2 Number of hospitals contributing to the National Antimicrobial Utilisation Surveillance Program, by peer group and jurisdiction, 2014 6

Table S3.3 Total-hospital antimicrobial usage rates (defined daily doses per 1000 occupied-bed days) by antimicrobial class, 2010–14 7

Table S3.4a Key indicators for appropriateness of antimicrobial prescribing in hospitals, by jurisdiction, 2014 8

Table S3.4b Key indicators for appropriateness of antimicrobial prescribing in hospitals, by peer group, 2014 9

Table S3.4c Key indicators for appropriateness of antimicrobial prescribing in hospitals, by remoteness, 2014 10

Table S3.4d Key indicators for appropriateness of antimicrobial prescribing in hospitals, by funding type, 2014 11

Table S3.4e Key indicators for appropriateness of antimicrobial prescribing in hospitals, by jurisdiction, peer group, remoteness and funding type, combined national result, 2014 11

Table S3.5 Appropriateness of antimicrobial prescribing in hospitals for the 20 most common indications, 2014 12

Table S3.6 Region of residence and socioeconomic status for patients prescribed systemic antibiotics in the community, 2014 14

Figure S3.1 Most commonly dispensed antibiotics in the community, by age group (3-point moving average), quarter 3, 2012 – quarter 4, 2014 15

Table S3.7 Residential aged care facilities participating in the Aged Care National Antimicrobial Prescribing Survey pilot, by jurisdiction, remoteness and provider type, 2015 17

Table S3.8 Prevalence of antimicrobial use and infection in residential aged care facilities, by jurisdiction, remoteness and provider type, 2015 18

Table S3.9 World Health Organization defined daily doses for antibacterial agents included in the National Antimicrobial Utilisation Surveillance Program annual report 19

Table S3.9a J01A Tetracyclines 19

Table S3.9b J01B Amphenicols 19

Table S3.9c J01C β-lactam antibacterials, penicillins 19

Table S3.9d J01D Other β-lactam antibacterials 20

Table S3.9e J01E Sulfonamides and trimethoprim 21

Table S3.9f J01F Macrolides, lincosamides and streptogramins 21

Table S3.9g J01G Aminoglycoside antibacterials 22

Table S3.9h J01M Quinolone antibacterials 22

Table S3.9i J01X Other antibacterials 23

Table S3.10 Antimicrobials included in analyses of Pharmaceutical Benefits Scheme and Repatriation Pharmaceutical Benefits Scheme data 23

AURA 2016 Chapter 4: antimicrobial resistance tables 25

Table S4.1 Acinetobacter baumannii resistance (all specimen sources), 2014 25

Table S4.2 Acinetobacter baumannii resistance, by clinical setting, 2014 25

Table S4.3 Escherichia coli resistance, by specimen source, 2014 25

Table S4.4 Klebsiella pneumoniae resistance, by specimen source, 2014 26

Table S4.5 Enterobacter cloacae resistance, by specimen source, 2014 27

Table S4.6 Enterococcus faecium resistance, by jurisdiction (blood culture isolates), 2014 29

Table S4.7 Enterococcus faecalis resistance, by jurisdiction (blood culture isolates), 2014 29

Table S4.8 Mycobacterium tuberculosis resistance to first-line antimycobacterial agents, 2005–14 30

Table S4.9 Mycobacterium tuberculosis notifications and resistance, by jurisdiction, 2014 31

Table S4.10 Neisseria gonorrhoeae decreased susceptibility and resistance, 2000–14 33

Table S4.11 Neisseria gonorrhoeae decreased susceptibility and resistance, by jurisdiction, 2014 34

Table S4.12 Neisseria gonorrhoeae decreased susceptibility to ceftriaxone (MIC 0.06–0.125 mg/L), by jurisdiction, 2009–14 34

Table S4.13 Percentage of Neisseria gonorrhoeae isolates with decreased susceptibility to ceftriaxone (MIC 0.06–0.125 mg/L), 2010–14 35

Table S4.14 Neisseria gonorrhoeae resistance to ciprofloxacin (MIC ≥1 mg/L), by jurisdiction, 2009–14 36

Table S4.15 Neisseria gonorrhoeae resistance to azithromycin (MIC ≥1 mg/L), by jurisdiction, 2009–14 37

Table S4.16 Neisseria gonorrhoeae resistance to penicillin (MIC ≥1 mg/L or penicillinase-producing N. gonorrhoeae), by jurisdiction, 2009–14 38

Table S4.17 Neisseria meningitidis resistance and decreased susceptibility, 2000–14 39

Table S4.18 Number of Neisseria meningitidis isolates at each penicillin MIC value, 2006–14 39

Table S4.19 Neisseria meningitidis decreased susceptibility to penicillin (MIC 0.06–0.50 mg/L), by jurisdiction, 2009–14 40

Table S4.20 Neisseria meningitidis resistance to penicillin (MIC ≥1 mg/L), by jurisdiction, 2002–12 41

Table S4.21 Neisseria meningitidis resistance to rifampicin (MIC ≥1 mg/L), by jurisdiction, 2001–14 41

Table S4.22 Pseudomonas aeruginosa resistance (all specimen sources), 2014 42

Table S4.23 Pseudomonas aeruginosa resistance, by clinical setting, 2014 42

Table S4.24 Salmonella species (nontyphoidal) resistance, by specimen source, 2014 43

Table S4.25 Salmonella species (typhoidal) resistance (blood culture isolates), 2014 44

Table S4.26 Salmonella species (nontyphoidal) resistance, by clinical setting, 2014 44

Table S4.27 Shigella species resistance (faecal isolates), 2014 45

Table S4.28 Shigella species resistance, by clinical setting, 2014 45

Table S4.29 Staphylococcus aureus resistance, by specimen source, 2014 46

Table S4.30 Staphylococcus aureus resistance, by clinical setting, 2014 46

Table S4.31 Staphylococcus aureus resistance, by jurisdiction (blood culture isolates), 2014 48

Table S4.32 Methicillin-resistant Staphylococcus aureus resistance, by specimen source, 2014 50

Table S4.33 Methicillin-resistant Staphylococcus aureus resistance, by clinical setting, 2014 50

Table S4.34 Methicillin-resistant Staphylococcus aureus resistance, by jurisdiction (blood culture isolates), 2014 52

Table S4.35 Methicillin-resistant Staphylococcus aureus resistance, by healthcare-associated and community-associated clones (blood culture isolates), 2014 54

Table S4.36 Methicillin-resistant Staphylococcus aureus healthcare-associated and community-associated clones, by jurisdiction (blood culture isolates), 2014 54

Table S4.37 Streptococcus agalactiae resistance (all specimen sources), 2014 55

Table S4.38 Streptococcus agalactiae resistance, by clinical setting, 2014 55

Table S4.39 Streptococcus pneumoniae resistance, by specimen source, 2014 55

Table S4.40 Streptococcus pneumoniae resistance, by clinical setting, 2014 56

Table S4.41 Streptococcus pyogenes resistance (all specimen sources), 2014 56

Table S4.42 Streptococcus pyogenes resistance, by clinical setting, 2014 57